Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor

Sabine Borngraeber, Mary Jane Budny, Grazia Chiellini, Suzana T. Cunha-Lima, Marie Togashi, Paul Webb, John D. Baxter, Thomas (Tom) Scanlan, Robert J. Fletterick

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β. The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3′ position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-Å resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3-4 Å in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex associates with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. Our data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.

Original languageEnglish (US)
Pages (from-to)15358-15363
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume100
Issue number26
DOIs
StatePublished - Dec 23 2003
Externally publishedYes

Fingerprint

Thyroid Hormone Receptors
Hydrophobic and Hydrophilic Interactions
Hormones
Ligands
Cytoplasmic and Nuclear Receptors
Endocrine System Diseases
Thyroid Hormones
Iodine
Thyroid Gland
Protein Isoforms
Proteins
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Borngraeber, S., Budny, M. J., Chiellini, G., Cunha-Lima, S. T., Togashi, M., Webb, P., ... Fletterick, R. J. (2003). Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proceedings of the National Academy of Sciences of the United States of America, 100(26), 15358-15363. https://doi.org/10.1073/pnas.2136689100

Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. / Borngraeber, Sabine; Budny, Mary Jane; Chiellini, Grazia; Cunha-Lima, Suzana T.; Togashi, Marie; Webb, Paul; Baxter, John D.; Scanlan, Thomas (Tom); Fletterick, Robert J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, No. 26, 23.12.2003, p. 15358-15363.

Research output: Contribution to journalArticle

Borngraeber, S, Budny, MJ, Chiellini, G, Cunha-Lima, ST, Togashi, M, Webb, P, Baxter, JD, Scanlan, TT & Fletterick, RJ 2003, 'Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor', Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15358-15363. https://doi.org/10.1073/pnas.2136689100
Borngraeber, Sabine ; Budny, Mary Jane ; Chiellini, Grazia ; Cunha-Lima, Suzana T. ; Togashi, Marie ; Webb, Paul ; Baxter, John D. ; Scanlan, Thomas (Tom) ; Fletterick, Robert J. / Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. In: Proceedings of the National Academy of Sciences of the United States of America. 2003 ; Vol. 100, No. 26. pp. 15358-15363.
@article{52cf944af39b4d79a436040b0dc0ee72,
title = "Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor",
abstract = "Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β. The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3′ position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-{\AA} resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3-4 {\AA} in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex associates with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. Our data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.",
author = "Sabine Borngraeber and Budny, {Mary Jane} and Grazia Chiellini and Cunha-Lima, {Suzana T.} and Marie Togashi and Paul Webb and Baxter, {John D.} and Scanlan, {Thomas (Tom)} and Fletterick, {Robert J.}",
year = "2003",
month = "12",
day = "23",
doi = "10.1073/pnas.2136689100",
language = "English (US)",
volume = "100",
pages = "15358--15363",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "26",

}

TY - JOUR

T1 - Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor

AU - Borngraeber, Sabine

AU - Budny, Mary Jane

AU - Chiellini, Grazia

AU - Cunha-Lima, Suzana T.

AU - Togashi, Marie

AU - Webb, Paul

AU - Baxter, John D.

AU - Scanlan, Thomas (Tom)

AU - Fletterick, Robert J.

PY - 2003/12/23

Y1 - 2003/12/23

N2 - Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β. The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3′ position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-Å resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3-4 Å in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex associates with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. Our data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.

AB - Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β. The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3′ position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-Å resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3-4 Å in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex associates with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. Our data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.

UR - http://www.scopus.com/inward/record.url?scp=0347364651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347364651&partnerID=8YFLogxK

U2 - 10.1073/pnas.2136689100

DO - 10.1073/pnas.2136689100

M3 - Article

C2 - 14673100

AN - SCOPUS:0347364651

VL - 100

SP - 15358

EP - 15363

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -